Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

14550

Enrollment

INDUSTRY

Sponsor class

Conditions

Arteriosclerosis
Hypercholesterolaemia

Interventions

DRUG: Enlicitide Decanoate
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC